Review: aging-related metabolic dysregulation in senile osteoporosis
This review argues that senile osteoporosis involves cellular senescence, metabolic dysfunction and systemic imbalance, not only hormonal decline; approved drugs remain central to fracture prevention, while senescence- and metabolism-targeting strategies are still experimental. [1]
Automatic summary · not editorially reviewed
The key findings
The review reports that senile osteoporosis is not driven solely by age-related hormonal decline but by a network of processes including stem cell senescence, mitochondrial dysfunction, oxidative stress, inflammation and disturbed glucose and lipid metabolism. [1]
These alterations are described as disrupting bone remodeling through pathways such as RANKL/OPG, Wnt/β-catenin, AMPK/SIRT1, NF-κB and PI3K/Akt/mTOR, impairing osteogenesis and enhancing osteoclastogenesis. [1]
Approved treatments such as bisphosphonates, denosumab, teriparatide, abaloparatide and romosozumab remain central to fracture prevention but do not fully reverse skeletal aging; senescence- and metabolism-targeting strategies are still under investigation. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- People with senile osteoporosis, discussed in a review of aging-related skeletal degeneration.
- Summary based on
- Study abstract
- Original publication
- July 27, 2026
Review scope: senile osteoporosis mechanisms
The review summarizes recent advances in understanding senile osteoporosis, focusing on how cellular senescence, metabolic dysfunction and systemic homeostatic imbalance interconnect in age-related skeletal degeneration. It reports emerging evidence that senile osteoporosis is not driven solely by age-related hormonal decline but by a network of processes: senescence of bone marrow mesenchymal stem cells, accumulation of the senescence-associated secretory phenotype, mitochondrial dysfunction, oxidative stress, chronic low-grade inflammation, and disturbances in glucose and lipid metabolism.
Supporting source [1]
Signaling pathways and bone remodeling effects
According to the review, these alterations disrupt bone remodeling through key signaling pathways, including RANKL/OPG, Wnt/β-catenin, AMPK/SIRT1, NF-κB and PI3K/Akt/mTOR. Together, the described mechanisms impair osteogenesis, enhance osteoclastogenesis, deteriorate bone microarchitecture and increase skeletal fragility. The review suggests this broader framework may explain why conventional antiresorptive therapies, although effective in reducing bone resorption, often fail to fully restore the structural and functional deficits of the aging skeleton.
Supporting source [1]
Approved drugs versus experimental geroscience strategies
The review states that senile osteoporosis should be viewed as a systemic aging-related disorder involving both deterioration of the local bone microenvironment and whole-body metabolic dysregulation. Current evidence-based pharmacological treatments, including bisphosphonates, denosumab, teriparatide, abaloparatide and romosozumab, remain central to fracture prevention and bone mass preservation, but do not fully reverse the biological processes of skeletal aging. Emerging strategies targeting cellular senescence, the senescence-associated secretory phenotype, mitochondrial dysfunction, oxidative stress, nutrient-sensing pathways and gut microbiota are under active investigation and may complement established therapies in the future. The review stresses that a clearer distinction between approved anti-osteoporotic drugs and experimental geroscience-based interventions is essential.
Supporting source [1]
How to interpret this
This is an abstract of a narrative review; the full text was not reviewed. It summarizes mechanisms and emerging strategies without reporting a new study design, sample, follow-up or outcome data. Proposed senescence-, metabolism- and microbiota-targeting strategies are described as under active investigation, not as established treatments.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bai R, Huang Z, Tian X, Liu Y, Wang Y, Su Y, Li M, Cheng C, Wu J, Zha Y, Lu S. · europepmc.org · July 27, 2026